Evidence map›Paper›PMID 29903991›Full record

ArticleInternational journal of molecular sciences2018

Synergistic Antitumor Effect of Oligogalacturonides and Cisplatin on Human Lung Cancer A549 Cells.

Cian-Song Huang, Ai-Chun Huang, Ping-Hsiu Huang, Diana Lo, Yuh-Tai Wang, Ming-Chang Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Cian-Song HuangDepartment of Food Science, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan. abc340414@gmail.com.
Ai-Chun HuangDepartment of Leisure, Recreation and Tourism Management, Tzu Hui Institute of Technology, Pingtung 92601, Taiwan. justice8j@gmail.com.
Ping-Hsiu HuangDepartment of Food Science, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan. hugh0530@gmail.com.ORCID 0000-0001-5454-6058
Diana LoDepartment of Food Technology, Bina Nusantara University, Alam Sutera Campus, Alam Sutera, Tangerang 15143, Indonesia. dione_lovincie@binus.edu.
Yuh-Tai WangLife Science Center, Hsing Wu University, LinKou District, New Taipei City 24452, Taiwan. 089008@mail.hwu.edu.tw.
Ming-Chang WuDepartment of Food Science, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan. mcwu@mail.npust.edu.tw.
National Pingtung University of Science and Technology · TWBinus University · IDHsing Wu University · TWTzu Hui Institute of Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin (DPP), a clinically potent antineoplastic agent, is limited by its severe adverse effects. The aim of this study was to investigate the effect of oligogalacturonides (OGA) and DDP on human lung cancer A549 cells. The combined use of OGA and DDP had a synergistic effect on the growth inhibition of A549 cells, changed the cell cycle distribution, and enhanced apoptotic response, especially in sequential combination treatment group of DDP 12 h + OGA 12 h. Western blot analyses showed that the combination treatment of OGA and DDP upregulated Bax, p53, and Caspase-3 and downregulated Bcl-2 proteins. More importantly, DDP-induced toxicity was attenuated by OGA and DDP combination treatment in normal HEK293 cells. Our data suggests that the combined use of OGA from natural sources and DDP could be an important new adjuvant therapy for lung cancer as well as offer important insights for reducing kidney toxicity of DDP and delaying the development of DDP resistance.

Indexed as

Antineoplastic AgentsApoptosisCaspase 3Cell CycleCell Line, TumorCell ProliferationCisplatinDrug SynergismHEK293 CellsHumansOligosaccharidesProto-Oncogene Proteins c-bcl-2Tumor Suppressor Protein p53Antineoplastic AgentsCaspase 3Cisplatinoligogalacturonic acidOligosaccharidesProto-Oncogene Proteins c-bcl-2Tumor Suppressor Protein p53adjuvant therapycisplatinoligogalacturonidessynergistic effect

Identifiers

PMID29903991
PMCPMC6032352
OpenAlexW2808055121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.